AVPR1A and cardiac hypertrophy: The regulation of cardiac hypertrophy by miR-208 pathway was affected by both drugs, as V1aR (targeted by relcovaptan) is linked to cardiac hypertrophy, and V2R (targeted by tolvaptan) may have therapeutic potential in heart failure [69].